Author

Manuel Häckl

Observed names: M. Häckl, MANUEL HÄCKL

Institution: Basilea Pharmaceutica (Switzerland)

Observed institutions: Roche Pharma AG (Germany), Basilea Pharmaceutica (Switzerland)

OpenAlex ID: A5050978146

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma

2021 · Stephan Braun, Paul McSheehy, et al. · Expert Opinion on Investigational Drugs · 18

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations

2024 · Andrea Necchi, Rodryg Ramlau, et al. · JNCI Cancer Spectrum · 10

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

2019 · WOLFGANG SCHULTZE-SEEMANN, HOLGER SCHULZ, et al. · Anticancer Research · 5

Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.

2023 · Andrea Necchi, Tilman Todenhöfer, et al. · Journal of Clinical Oncology · 4

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01

2026 · Mitesh J. Borad, Michele Droz dit Busset, et al. · Hepatology

Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study

2023 · A. Necchi, T. Todenhöfer, et al. · European Urology

Works count: 6

Citation count: 37

H-index: 4

I10-index: 2